Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18914634 | 0.88 | KDM4E (0.38) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL18914274 | 0.86 | HTR2A (0.38) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL18959737 | 0.86 | HTR2A (0.38) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL17868304 | 0.86 | HTR2A (0.38) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL18908181 | 0.84 | L3MBTL1 (0.36) | KDM4EHTR2AHTR2CCYP2D6USP2 | |
| SCHEMBL18961579 | 0.84 | KDM4E (0.37) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL18908174 | 0.84 | HTR2A (0.39) | KDM4EHTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL18964398 | 0.83 | KDM4E (0.40) | KDM4EHTR2AHTR2CHTR1ADRD2 | |
| SCHEMBL18972008 | 0.82 | KDM4E (0.38) | KDM4EHTR2AHTR2CHTR1ADRD2 | |
| SCHEMBL18909762 | 0.82 | CA1 (0.44) | SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380478-B1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | KDM4E 1195/4885HTR2A 4837/4885HTR2C 4824/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | KDM4E 2522/4885HTR2A 4800/4885HTR2C 4538/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | KDM4E 2407/4885HTR2A 4785/4885HTR2C 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.